Skip to main content
MLAB logo

Mesa Laboratories, Inc. (MLAB) Stock: Price, Forecast & Analyst Target

Mesa Laboratories, Inc. (MLAB) — MoonshotScore 42/100 (Weak band), calculated Nov 18, 2026. Price $137.81 (+2.38%), as of the Nov 18, 2026 trading session; market cap $775M.

Educational signal · not a buy or sell recommendation · How to read this

$137.81 +$3.21 (+2.38%) Market Cap $775M

Mesa Laboratories, Inc. · MLAB · NASDAQ

Mesa Laboratories, Inc. is a technology company specializing in life sciences tools and quality control products.

Price as of Nov 18, 2026

Key Statistics

42 of 100

MoonshotScore v2 · Mesa Laboratories (MLAB)

Weak
Business Quality Elite (83)
Financial Safety Okay (56)
Valuation Full (59)
Growth Durability Compounding (94)
Momentum Surging (95)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and elite growth, but a full valuation. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 1 of the last 4 reports
  • Altman Z 2.43 · Piotroski F 7
  • ROE 3.6% · ROA 3.9% · current ratio 1.91

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MLAB (57 recorded, newest six shown)
RecordedScoreBand
42Weak
42Weak
42Weak
42Weak
42Weak
42Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$137.81
Change on the day+2.38%
52-week range$69.51 – $144.35
Market capitalisation$775M—
Price / earnings (trailing)114.07
Shares traded on the day74.9K

Price & events

Other perspectives

Council score for Mesa Laboratories (MLAB): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Neutral
Growth Durability Strong
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Overvalued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Neutral
ROE Weak
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Mesa Laboratories (MLAB), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Mesa Laboratories, Inc. (MLAB) is listed on NASDAQ. It employs 717 people and is led by Siddhartha C. Kadia. The market values it at $775M.

2 · Latest results

What do the latest results show for Mesa Laboratories (MLAB)?

Short answer · as of

Against analyst estimates the company has EPS beat 1 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$61M$2M$0.45 (diluted)
Q3 FY2026$65M$4M$0.65 (diluted)
Q4 FY2026$64M-$4M-$0.75 (diluted)
Q1 FY2027$60M$3M$0.49 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Mesa Laboratories (MLAB)?

Short answer

The MoonshotScore pillars rate business quality, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 2.43 · Piotroski F 7. Trailing ratios: ROE 3.6% · ROA 3.9% · current ratio 1.91.

4 · What to check next?

What should you watch next at Mesa Laboratories (MLAB)?

Short answer · as of

Current published price targets run low $110.00 · high $110.00 · consensus $110.00 · median $110.00 against a quoted price of $137.81 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Mesa Laboratories compare with its peers?

Short answer

Mesa Laboratories's score ranks 4th of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Thermo Fisher Scientific Inc. (TMO) Named competitor$692.74 Nov 18, 2026$257B70 5-pillar Nov 18, 2026
3M Company (MMM) Named competitor$181.05 Nov 18, 2026$93.6B66 5-pillar Nov 18, 2026
Inspira Technologies Oxy B.H.N. Ltd. (QTEX) Same industry, near in market value$1.12 Nov 18, 2026$75.1M45 5-pillar Nov 18, 2026
Mesa Laboratories (MLAB) — this page$137.81$775M42
SHOULDER INNOVATIONS, INC. (SI) Same industry, near in market value$20.65 Nov 18, 2026$432M34 5-pillar Nov 18, 2026
iTonic Holdings Ltd. (ITOC) Same industry, near in market value$1.57 Nov 18, 2026$11.5M29 5-pillar Nov 18, 2026
PerkinElmer, Inc. (PKI) Named competitor$115.24 Sep 11, 2026$14.5B— Model unavailable

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$110.00 – $110.00
Consensus target
$110.00
Median target
$110.00

Consensus record · Captured .

Measured against a quoted price of $137.81 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MLAB in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MLAB in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Mesa Laboratories (MLAB)?

Read these with our analysis →

Common Questions About MLAB

These answers are editorial: 1 of these 9 answers is drawn from the MLAB research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for MLAB?

MLAB carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is MLAB a good stock to buy?

Stock Expert AI does not rate MLAB buy, sell or hold. Mesa Laboratories, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MLAB stock price today?

The last price recorded for Mesa Laboratories, Inc. (MLAB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MLAB price target?

The analyst consensus price target for Mesa Laboratories, Inc. (MLAB), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for MLAB?

Mesa Laboratories faces several risks, including regulatory challenges that could delay product approvals and market entry. Additionally, intense competition from larger players in the life sciences sector poses a threat, along with potential economic downturns that may impact healthcare spending and investment.

What are the key factors to evaluate for MLAB?

Mesa Laboratories, Inc. (MLAB) holds a MoonshotScore in the low range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Mesa's automated systems for protein analysis and peptide synthesis are well-positioned to meet the increasing demand for innovative therapies and research solutions. Not financial advice.

How frequently does MLAB data refresh on this page?

MLAB's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MLAB's recent stock price performance?

Mesa Laboratories, Inc. (MLAB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple life sciences segments. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MLAB overvalued or undervalued right now?

The trailing P/E of Mesa Laboratories, Inc. (MLAB) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.